{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:54:01Z","timestamp":1760853241968,"version":"build-2065373602"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.jalz.2006.05.2347","type":"journal-article","created":{"date-parts":[[2006,10,12]],"date-time":"2006-10-12T07:31:26Z","timestamp":1160638286000},"page":"287-293","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Commentary on \u201cOptimal design of clinical trials for drugs designed to slow the course of Alzheimer\u2109s disease.\u201d Biochemical biomarkers of late\u2010life dementia"],"prefix":"10.1002","volume":"2","author":[{"given":"Christopher M.","family":"Clark","sequence":"first","affiliation":[{"name":"Department of Neurology University of Pennsylvania Philadelphia Pennsylvania"},{"name":"Alzheimer\u2109s Disease Center University of Pennsylvania Philadelphia Pennsylvania"},{"name":"Institute on Aging University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Pratico","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley M.","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Leight","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine University of Pennsylvania Philadelphia Pennsylvania"},{"name":"Center for Neurodegenerative Disease Research University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon X.","family":"Xie","sequence":"additional","affiliation":[{"name":"Alzheimer\u2109s Disease Center University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine University of Pennsylvania Philadelphia Pennsylvania"},{"name":"Alzheimer\u2109s Disease Center University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia M.-Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine University of Pennsylvania Philadelphia Pennsylvania"},{"name":"Alzheimer\u2109s Disease Center University of Pennsylvania Philadelphia Pennsylvania"},{"name":"Center for Neurodegenerative Disease Research University of Pennsylvania Philadelphia Pennsylvania"},{"name":"Institute on Aging University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Q.","family":"Trojanowski","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine University of Pennsylvania Philadelphia Pennsylvania"},{"name":"Alzheimer\u2109s Disease Center University of Pennsylvania Philadelphia Pennsylvania"},{"name":"Center for Neurodegenerative Disease Research University of Pennsylvania Philadelphia Pennsylvania"},{"name":"Institute on Aging University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,10]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"crossref","unstructured":"M.S.Forman J.Farmer J.K.Johnson C.M.Clark S.E.Arnold H.B.Coslett et al.Frontotemporal dementia: Clinicopathological correlations. Ann Neurol.2006(In press)","DOI":"10.1002\/ana.20873"},{"issue":"5","key":"e_1_2_10_3_2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ana.20477","article-title":"Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer\u2109s disease","volume":"57","author":"Grossman M.","year":"2005","journal-title":"Ann Neurol"},{"issue":"4","key":"e_1_2_10_4_2","first-page":"521","article-title":"Biological markers for therapeutic trials in Alzheimer\u2109s disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer\u2109s disease","volume":"24","author":"Frank R.A.","year":"2003","journal-title":"Neurobiol Aging"},{"issue":"1","key":"e_1_2_10_5_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1385\/MN:24:1-3:087","article-title":"CSF total tau, Ab42 and phosphorylated tau protein as biomarkers for Alzheimer\u2109s disease","volume":"24","author":"Blennow K.","year":"2001","journal-title":"Mol Neurobiol"},{"issue":"12","key":"e_1_2_10_6_2","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/archneur.60.12.1696","article-title":"Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?","volume":"60","author":"Clark C.M.","year":"2003","journal-title":"Arch Neurol"},{"issue":"1","key":"e_1_2_10_7_2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","article-title":"Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study","volume":"61","author":"Hampel H.","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"e_1_2_10_8_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1034\/j.1600-0404.107.s179.9.x","article-title":"Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer\u2109s disease in patients with mild cognitive impairment","volume":"179","author":"Andreasen N.","year":"2003","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"e_1_2_10_9_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/exnr.2000.7501","article-title":"CSF phosphorylated tau protein and mild cognitive impairment: a prospective study","volume":"166","author":"Arai H.","year":"2000","journal-title":"Exp Neurol"},{"issue":"4","key":"e_1_2_10_10_2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1212\/WNL.59.4.627","article-title":"CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects","volume":"59","author":"Buerger K.","year":"2002","journal-title":"Neurology"},{"issue":"3","key":"e_1_2_10_11_2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","article-title":"Association between CSF biomarkers and incipient Alzheimer\u2109s disease in patients with mild cognitive impairment: a follow-up study","volume":"5","author":"Hansson O.","year":"2006","journal-title":"Lancet Neurol"},{"issue":"7","key":"e_1_2_10_12_2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/archneur.55.7.937","article-title":"High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype","volume":"55","author":"Galasko D.","year":"1998","journal-title":"Arch Neurol"},{"issue":"2","key":"e_1_2_10_13_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1385\/JMN:17:2:119","article-title":"Biological markers and the treatment of Alzheimer\u2109s disease","volume":"17","author":"Galasko D.","year":"2001","journal-title":"J Mol Neurosci"},{"issue":"3","key":"e_1_2_10_14_2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta(42) in humans","volume":"59","author":"Fagan A.M.","year":"2006","journal-title":"Ann Neurol"},{"issue":"3","key":"e_1_2_10_15_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2796.2004.01381.x","article-title":"MRI and CSF studies in the early diagnosis of Alzheimer\u2109s disease","volume":"256","author":"Leon M.J.","year":"2004","journal-title":"J Intern Med"},{"issue":"1","key":"e_1_2_10_16_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/01.wad.0000191420.61260.a8","article-title":"The Role of biomarkers in clinical trials for Alzheimer disease","volume":"20","author":"Thal L.J.","year":"2006","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"8","key":"e_1_2_10_17_2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/jnen\/60.8.759","article-title":"Oxidative damage is the earliest event in Alzheimer disease","volume":"60","author":"Nunomura A.","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"issue":"12","key":"e_1_2_10_18_2","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1523\/JNEUROSCI.21-12-04183.2001","article-title":"Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis","volume":"21","author":"Pratico D.","year":"2001","journal-title":"J Neurosci"},{"issue":"1","key":"e_1_2_10_19_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.chemphyslip.2003.10.010","article-title":"Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases","volume":"128","author":"Montine K.S.","year":"2004","journal-title":"Chem Phys Lipids"},{"issue":"3","key":"e_1_2_10_20_2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ana.410440322","article-title":"Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer\u2109s disease","volume":"44","author":"Montine T.J.","year":"1998","journal-title":"Ann Neurol"},{"issue":"5","key":"e_1_2_10_21_2","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0002-9440(10)62347-4","article-title":"Fatty acid oxidation in the pathogenesis of Alzheimer\u2109s disease","volume":"166","author":"Montine T.J.","year":"2005","journal-title":"Am J Pathol"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.12.15.1777"},{"issue":"5","key":"e_1_2_10_23_2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9","article-title":"Increased 8,12-iso-iPF2a-VI in Alzheimer\u2109s disease: correlation of a noninvasive index of lipid peroxidation with disease severity","volume":"48","author":"Pratico D.","year":"2000","journal-title":"Ann Neurol"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.6.972"},{"issue":"2","key":"e_1_2_10_25_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/JAD-2004-6209","article-title":"Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer\u2109s disease","volume":"6","author":"Pratico D.","year":"2004","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"e_1_2_10_26_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.neurobiolaging.2005.07.003","article-title":"Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment","volume":"27","author":"Leon M.J.","year":"2006","journal-title":"Neurobiol Aging"},{"issue":"2","key":"e_1_2_10_27_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ana.10272","article-title":"Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer\u2109s disease","volume":"52","author":"Montine T.J.","year":"2002","journal-title":"Ann Neurol"},{"issue":"5","key":"e_1_2_10_28_2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0002-9440(10)63724-8","article-title":"12\/15-lipoxygenase is increased in Alzheimer\u2109s disease: possible involvement in brain oxidative stress","volume":"164","author":"Pratico D.","year":"2004","journal-title":"Am J Pathol"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526006047753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526006047753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.jalz.2006.05.2347","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2006.05.2347","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1016\/j.jalz.2006.05.2347","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2006.05.2347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:38:31Z","timestamp":1759927111000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1016\/j.jalz.2006.05.2347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10.1016\/j.jalz.2006.05.2347"],"URL":"https:\/\/doi.org\/10.1016\/j.jalz.2006.05.2347","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"type":"print","value":"1552-5260"},{"type":"electronic","value":"1552-5279"}],"subject":[],"published":{"date-parts":[[2006,10]]},"assertion":[{"value":"2006-10-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}